Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

RCKT Oct 20 '23 17.50 Call

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [N/A]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ rootItem.symbol ]]underlying price [[ rootItem.lastPrice ]] [[ rootItem.priceChange ]] ([[ rootItem.percentChange ]]) [[ rootItem.tradeTime ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
Help
Go To:
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Full Chart
Free Barchart Webinars! Live educational sessions using site features to explore today's markets.

Most Recent Stories

More News
Rocket Pharmaceuticals to Participate in the 8th Annual Evercore Healthcare Conference Business Wire - Tue Nov 25, 6:00AM CST

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need,...

RCKT : 3.47 (-1.14%)
Rocket Pharmaceuticals: Q3 Earnings Snapshot AP - Thu Nov 6, 3:09PM CST

Rocket Pharmaceuticals: Q3 Earnings Snapshot

RCKT : 3.47 (-1.14%)
Rocket Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Progress Business Wire - Thu Nov 6, 3:00PM CST

Pivotal Phase 2 trial of RP-A501 for Danon disease to resume in 1H 2026 KRESLADI™ for severe LAD-I on track for March 28, 2026 PDUFA date ...

RCKT : 3.47 (-1.14%)
Biologics Market Surges Toward $680B as FDA Accelerates Approval Pathways BayStreet.ca - Tue Nov 4, 8:30AM CST

Issued on behalf of Avant Technologies Inc. VANCOUVER – Baystreet.ca News Commentary – The global biologics industry is experiencing unprecedented expansion as the market surges toward $679.56...

AVAI : 0.2886 (-10.26%)
VRTX : 461.18 (-0.39%)
WST : 273.78 (-1.04%)
RCKT : 3.47 (-1.14%)
AXSM : 152.26 (-0.90%)
Rocket Pharmaceuticals’ FDA Resubmission for KRESLADI™ Accepted Tipranks - Wed Oct 15, 6:42AM CDT

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Rocket Pharmaceuticals...

RCKT : 3.47 (-1.14%)
Rocket Pharmaceuticals Announces FDA Acceptance of BLA Resubmission of KRESLADI™ for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I) Business Wire - Tue Oct 14, 6:00AM CDT

Prescription Drug User Fee Act (PDUFA) target action date is March 28, 2026 All primary and secondary endpoints were met, and KRESLADI™ was well tolerated ...

RCKT : 3.47 (-1.14%)
Rocket Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire - Fri Oct 10, 3:00PM CDT

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need,...

RCKT : 3.47 (-1.14%)
Rocket Pharmaceuticals Board Member Resigns in September Tipranks - Sat Oct 4, 4:14PM CDT

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. The latest...

RCKT : 3.47 (-1.14%)
Analysts Offer Insights on Healthcare Companies: Rocket Pharmaceuticals (RCKT), Summit Therapeutics (SMMT) and United Therapeutics (UTHR) Tipranks - Sat Oct 4, 8:14AM CDT

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Rocket Pharmaceuticals (RCKT – Research Report), Summit Therapeutics (SMMT – Research Report) and United...

SMMT : 18.22 (-0.87%)
RCKT : 3.47 (-1.14%)
UTHR : 506.65 (-1.55%)
Rocket Pharmaceuticals Withdraws FDA Application for Gene Therapy Tipranks - Sat Oct 4, 6:38AM CDT

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Rocket Pharmaceuticals...

RCKT : 3.47 (-1.14%)
More news for this symbol

RCKT Related stocks

Symbol Latest 3M %Chg
RCKT 3.47 +7.01%
Rocket Pharmaceuticals Inc
AZN 92.61 +25.54%
Astrazeneca Plc ADR
AMGN 331.09 +21.49%
Amgen Inc
GILD 124.67 +11.23%
Gilead Sciences Inc
VRTX 461.35 +19.60%
Vertex Pharmaceutic
BMY 54.47 +23.63%
Bristol-Myers Squibb Company

Business Summary

Rocket Pharmaceuticals, Inc. is an emerging, clinical-stage biotechnology company. It focused on developing first-in-class gene therapy treatment options for rare, undertreated diseases. Rocket Pharmaceuticals Inc., formerly known as Inotek Pharmaceuticals Corporation, is based in LEXINGTON, United States....

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot